“There’s been a lot of conversation around Kwesi Adofo-Mensah taking paternity leave, largely because it’s still rare in the ...

Earlier in January 2026, Viking Therapeutics reported that its obesity drug candidate VK2735 achieved 14.7% weight loss from baseline over 13 weeks in a Phase 2 trial, meeting primary and secondary ...

Both companies may succeed in this industry.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best US stocks to buy under $50. On January 12, Viking Therapeutics, ...

They could perhaps see sustained runs beyond this year.

We recently published 10 Big Names Delivering Outsized Gains. Viking Therapeutics Inc. (NASDAQ:VKTX) was one of the top performers on Wednesday. Viking Therapeutics grew its share prices by 11.89 ...

By Puyaan Singh Jan 12 (Reuters) - Weight-loss drug developer Viking Therapeutics CEO said on Monday that strategic interest in weight-loss drug deals is broader than it appears, as drugmakers seek to ...

Jan 12 (Reuters) - Weight-loss drug developer Viking Therapeutics (VKTX.O), opens new tab CEO said on Monday that strategic interest in weight-loss drug deals is broader than it appears, as drugmakers ...

These stocks have struggled over the past year but may possess plenty of upside in the future.

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...

The Lady Viking Invitational at Akron North High School featured a huge number of Greater Akron girls wrestlers who got a ...